Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab plus gemcitabine/carboplatin versus placebo plus gemcitabine/carboplatin in advanced urothelial carcinoma
2016-000250-35Phase 3Active
- Sponsor
- Roche
- Start
- Jun 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in transitional cell carcinoma (TCC) comparing Atezolizumab + gemcitabine + carboplatin with Placebo + gemcitabine + carboplatin (2 arms). Primary endpoints: Progression-free survival and Overall survival. Started Jun 2016; status: active.
02
Drugs
atezolizumab
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2016-000250-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000250-35.